Inherited Thrombophilias
Aetna considers genetic testing for inherited thrombophilias medically necessary when specific clinical indications or testing strategies are met; routine population screening is not recommended.
ALL of the following
Factor V Leiden genetic testing is medically necessary for members with an abnormal activated protein C (APC) resistance assay result and any of the following: asymptomatic female planning pregnancy or currently pregnant not taking anticoagulation with additional risk factors; first-degree relative with high-risk thrombophilia; first-degree relative with VTE before age 50; first unprovoked VTE at any age (especially <50); individual with a first VTE and a first-degree relative with VTE before age 50; recurrent VTE; venous thrombosis at unusual sites (eg, cerebral, mesenteric, portal, hepatic veins); VTE associated with oral contraceptives or hormone replacement therapy; VTE during pregnancy or puerperium.
Testing for prothrombin G20210A (F2) and consideration of combined testing (eg, F5 and F2) is appropriate when results will affect management, and when overlapping phenotypes or potentiation of risk is suspected.
Testing is medically necessary in relatives of individuals with documented pathogenic thrombophilia variants for the purpose of cascade/variant-specific testing when a causative familial mutation has been identified.
The American College of Medical Genetics (ACMG) does not recommend random population screening for Factor V Leiden; targeted testing prior to oral contraceptive use may be appropriate for women with personal or family history of venous thrombosis.
Interstitial Lung Disease (ILD)
Aetna considers genetic testing of SP-C (SFTPC) and ABCA3 mutations medically necessary in specific pediatric presentations of interstitial lung disease (ILD) where results will inform diagnosis and management.
ANY of the following
Infants presenting with acute respiratory failure in the absence of other explanations where surfactant dysfunction is suspected; genetic testing may obviate the need for lung biopsy.
Older children with chronic ILD presentation or a family history of ILD, especially when diagnostic imaging (radiographic patterns) or bronchoscopic findings are consistent with ILD.
Testing is indicated when identification of SP-C or ABCA3 mutations would alter management, guide prognosis, or inform family counseling.
Hypophosphatasia
Aetna considers genetic testing for pathogenic variants in ALPL medically necessary to confirm the diagnosis of hypophosphatasia when clinical and biochemical findings support the diagnosis.
ALL of the following
Clinical features and biochemical testing (low serum and bone alkaline phosphatase activity) suggest hypophosphatasia.
Molecular testing for bi-allelic pathogenic variants (or a heterozygous pathogenic variant, depending on clinical context) in ALPL is performed to confirm the diagnosis (prenatal context excepted where genetic diagnosis is essential).
Malignant Hyperthermia (MH) and Related Disorders
Aetna considers genetic testing for malignant hyperthermia susceptibility (MHS) medically necessary in the following circumstances and considers genetic testing otherwise investigational.
ANY of the following
Persons with a positive or equivocal contracture test (eg, CHCT/IVCT) to determine the presence of a specific RYR1 variant considered causative for MH by the European Malignant Hyperthermia Group (EMHG) to enable predictive testing in relatives.
At-risk relatives of persons with clinically confirmed MHS when a known familial RYR1 variant (considered causative by EMHG) has been identified — mutation-specific testing for cascade predictive purposes.
Patients with a clinical history suspicious for MH (eg, acute MH episode, masseter muscle rigidity, postoperative myoglobinuria, heat- or exercise-induced rhabdomyolysis) who are unable or unwilling to undergo contracture testing.
Genetic Testing for Mitochondrial Disorders
Aetna considers molecular genetic testing for suspected mitochondrial disorders medically necessary when testing strategy and specimen selection are appropriate to the clinical presentation.
ALL of the following
Clinical features suggestive of a mitochondrial disorder (eg, multisystem involvement such as ataxia, cardiomyopathy, optic neuropathy, exercise intolerance, lactic acidosis, seizures) or syndromic presentations (eg, MELAS, MERRF, Kearns-Sayre, LHON) where a genetic etiology is likely.
Testing strategy tailored to the suspected etiology: targeted testing of nuclear genes when a nuclear inheritance pattern is suspected, sequencing of the mitochondrial genome (mtDNA) and/or targeted mtDNA mutation analysis when maternal inheritance or known mtDNA variants are suspected; for many mtDNA variants, testing of muscle tissue may be required because blood testing can be falsely negative.
Use of multi-gene panels or genomic testing (eg, whole-exome sequencing, whole mitochondrial genome sequencing) is appropriate when single-gene testing or panels are non-diagnostic and a genetic diagnosis would impact management, prognosis, or reproductive counseling.
Genetic Testing for Familial Malignant Melanoma (CDKN2A)
Aetna considers CDKN2A (familial melanoma) genetic testing limited and generally not recommended outside research or very specific contexts because test results rarely alter management; testing may be considered when results would change clinical care or in the context of research/clinical trials.
ANY of the following
Testing may be considered in families with multiple affected first-degree relatives spanning generations or a high pre-test probability of a CDKN2A pathogenic variant when results would alter clinical management (eg, influence screening recommendations beyond standard dermatologic surveillance) or for enrollment in clinical trials.
Aetna considers routine CDKN2A testing for familial malignant melanoma not appropriate outside research settings given limited impact on patient management and uncertain clinical utility.
Maturity-Onset Diabetes of the Young (MODY)
Aetna considers genetic testing for MODY (GCK, HNF1A, HNF4A) medically necessary when identification of the genetic subtype will affect treatment or management decisions.
ALL of the following
Person has hyperglycemia or non–insulin-dependent diabetes with a family history of abnormal glucose metabolism in at least 2 consecutive generations, and the individual or one or more family members were diagnosed before age 25.
Identification of a pathogenic variant would influence management (eg, choice of oral agents such as sulfonylureas for HNF1A/HNF4A, or conservative/no pharmacologic therapy for GCK-related MODY).
Menkes Disease
Aetna considers genetic testing for Menkes disease medically necessary for children with biochemical evidence consistent with Menkes disease.
ALL of the following
Child has low serum copper and low serum ceruloplasmin concentrations consistent with Menkes disease.
Molecular genetic testing (ATP7A sequence analysis and, if indicated, deletion/duplication analysis) is performed to confirm the diagnosis and guide management and genetic counseling.
May-Hegglin Anomaly and Related Disorders (MYH9)
Aetna considers genetic testing for MYH9-associated disorders (eg, May-Hegglin anomaly) limited and appropriate when clinical presentation suggests an inherited giant platelet disorder or a MYH9-related phenotype.
ANY of the following
Genetic testing may be considered when clinical features (giant platelets, thrombocytopenia, Dohle-like cytoplasmic inclusions, family history, renal disease, sensorineural hearing loss) suggest a MYH9-associated disorder and results would affect diagnosis or reproductive counseling.
Genetic testing is not recommended for general population screening or routine evaluation of thrombocytopenia without features suggestive of a hereditary platelet disorder.
Initial and Salvage (Genomic) Testing
Initial genomic testing (eg, whole exome sequencing) and salvage strategies (eg, reflex RNA testing, mRNA analysis) are considered medically necessary when they meet condition-specific criteria and when results are expected to impact management, clarify uncertain DNA findings, or avoid invasive procedures.
ANY of the following
Initial genomic testing (WES/GS) is considered medically necessary when condition-specific WES/GS criteria are met (see Whole Exome Sequencing criteria): genetic etiology likely, evaluation by a board-certified geneticist, counseling provided, alternate etiologies considered, and WES is more efficient than sequential testing.
Salvage testing strategies (including targeted mRNA/RNA analysis or repeat sequencing/re-analysis of prior genomic data) are considered medically necessary when prior DNA testing yielded variants of uncertain significance that affect splicing or when additional testing (eg, RNA analysis) is likely to resolve classification or would change management.
Concurrent or reflex mRNA (RNA) sequence analysis alongside DNA testing may be appropriate in hereditary cancer and other genes where predicted splicing variants are detected and where RNA testing can clarify variant impact and change clinical management.
RNA (mRNA) Sequence Analysis — Indications
Aetna considers RNA (mRNA) sequence analysis (RGT) alongside DNA genetic testing appropriate when results will resolve variants of uncertain significance affecting splicing or will otherwise change clinical management.
ANY of the following
RNA testing is considered medically necessary when DNA testing identifies a variant predicted to affect splicing or when a VUS is suspected to alter mRNA splicing and RNA analysis is likely to clarify classification and affect patient management (eg, hereditary cancer genes, selected diagnostic panels).
RNA testing may be offered to re-classify inconclusive variants from prior DNA genetic testing when reclassification would change clinical recommendations for the patient or family (eg, surveillance, risk-reduction surgery, targeted therapies, reproductive decision-making).
Routine use of RNA testing in the absence of a specific indication (eg, no splice-predictive variant or clinical utility) is not recommended.